ramirez, I. et al. 2022. Benefits of a National Program for Adverse Drugs Reactions (ADRS) Surveillance in Diabetic Patients. Journal of Drug Delivery and Therapeutics. 12, 4-S (Aug. 2022), 40–42. DOI:https://doi.org/10.22270/jddt.v12i4-S.5618.